Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Kutty Selva Nandakumar
 -- 1650 2023-11-07 11:12:33 |
2 Format correct
Wendy Huang
 + 1 word(s) 1651 2023-11-07 11:27:38 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Nandakumar, K.S.; Fang, Q.; Wingbro Ågren, I.; Bejmo, Z.F. Pathogenesis and Diagnosis of Rheumatoid Arthritis. Encyclopedia. Available online: https://encyclopedia.pub/entry/51241 (accessed on 18 November 2024).
Nandakumar KS, Fang Q, Wingbro Ågren I, Bejmo ZF. Pathogenesis and Diagnosis of Rheumatoid Arthritis. Encyclopedia. Available at: https://encyclopedia.pub/entry/51241. Accessed November 18, 2024.
Nandakumar, Kutty Selva, Qinghua Fang, Isabella Wingbro Ågren, Zoe Fuwen Bejmo. "Pathogenesis and Diagnosis of Rheumatoid Arthritis" Encyclopedia, https://encyclopedia.pub/entry/51241 (accessed November 18, 2024).
Nandakumar, K.S., Fang, Q., Wingbro Ågren, I., & Bejmo, Z.F. (2023, November 07). Pathogenesis and Diagnosis of Rheumatoid Arthritis. In Encyclopedia. https://encyclopedia.pub/entry/51241
Nandakumar, Kutty Selva, et al. "Pathogenesis and Diagnosis of Rheumatoid Arthritis." Encyclopedia. Web. 07 November, 2023.
Pathogenesis and Diagnosis of Rheumatoid Arthritis
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms242115883

Rheumatoid arthritis (RA) is a systemic, chronic, autoimmune disease categorized by synovial inflammation due to the infiltration of T cells, B cells, neutrophils, and macrophages, destroying articular joints and bone architecture. RA is primarily associated with inflammation within synovial joints. All peripheral joints can be affected in RA, but the most affected are those of the hands, feet, and knees. Although RA’s etiology is still unknown, several factors contributing to RA have been identified. Among them are the susceptibility genes, disease-causing immune cells, and cytokine and signal transduction networks that promote inflammation.

rheumatoid arthritis inflammation immune system T cells B cells pathogenesis clinical symptoms

1. Introduction

Rheumatoid arthritis (RA) affects 0.5–1% of the population worldwide, in a female/male ratio of 3:1, and is most common among those aged 40–70. RA is primarily associated with inflammation within synovial joints. All peripheral joints can be affected in RA, but the most affected are those of the hands, feet, and knees [1]. Although RA’s etiology is still unknown, several factors contributing to RA have been identified. Among them are the susceptibility genes, disease-causing immune cells, and cytokine and signal transduction networks that promote inflammation. Various therapeutic strategies have been developed to target these factors, including TNF-α neutralizing agents, anti-IL-6, and B-cell-depleting antibodies [2]. Although none of these therapeutic strategies can cure the disease, some have proven more effective than others in ameliorating joint inflammation.

2. Pathogenesis and Clinical Symptoms of Rheumatoid Arthritis

RA is a systemic, chronic, autoimmune disease categorized by synovial inflammation due to the infiltration of T cells, B cells, neutrophils, and macrophages, destroying articular joints and bone architecture. However, RA is not a homogenous disease but instead a syndrome of several sub-phenotypes. RA occurs when the body’s immune system attacks its proteins, so-called self-antigens. The pathogenesis behind RA is a combination of epigenetic, environmental, and genetic factors. Environmental factors contributing to immune system activation and inflammation in RA include smoking, microorganisms, and pollution. When these factors encounter mucous membranes, they can cause local inflammation and epigenetic modifications, including DNA methylation and acetylation [3]. Post-translational modifications (PTMs) of proteins could also occur due to environmental factors, which change a protein’s function and structure. For example, citrullination of proteins changes the protein’s structure, function, and interactions with the immune cells. Arthritis in the joint involves a multicellular inflammatory process involving infiltration of lymphocytes and granulocytes into the articular cartilage, proliferation of synovial fibroblasts and macrophages, and neovascularization of the synovial lining surrounding the joints. This proliferative process induces swelling, erythema, and pain in multiple joints, leading to destruction and loss of bone density and architecture.
Our body initiates the joint-specific attack by producing autoantibodies [4][5] because of aberrant activation of the B cells recognizing either a self- or cross-reactive antigen. The antibodies, after binding to the joint-specific antigens like collagen type II, present abundantly in the articular cartilage, and other cartilage matrix proteins (cartilage oligomeric matrix protein, collagen type XI) deposited on the cartilage surface could activate the complement system and attract phagocytes to the inflammation site. Active immunization of mice with these cartilage matrix proteins or passive transfer of antibodies specific to them induced arthritis. In addition, serum from K/BxN mice containing anti-glucose-6 phosphatase isomerase (GPI) also induced arthritis in mice due to the binding of these antibodies to GPI deposited on the cartilage surface. Because of the increased immune attack on the joints by the effector cells, there can be a great deal of damage to the articular joints by further activating the complement system through three different pathways (classical, alternative, and lectin pathways) involving several proteases [6]. Mainly, the alternative pathway is involved in activating the terminal pathway. Thus, therapeutic efforts in RA might be improved if the treatment includes its inhibition [7] and the Fc-gamma (FcγRs)-bearing immune effector cells [8][9], like macrophages, dendritic cells, neutrophils, and others. This makes an early diagnosis more crucial for providing optimal therapy [4]. Relative contributions of complement and FcR-mediated inflammatory pathways to the antigen–antibody complex-dependent inflammatory responses could vary depending on many factors. These include antibody isotype and titer and the site of immune complex deposition. Concerning the Ig isotype, FcγR mechanisms could predominate with immune complexes comprised of non-complement-fixing antibodies or deposit in the locations with abundant resident FcγR-bearing inflammatory cells. Conversely, complement-driven inflammation may dominate when FcγR poorly binds immune complexes containing Ig-constant regions or when leukocytes must be attracted to an inflammatory site.
Many disease-specific autoantibodies are present in different autoimmune diseases. In arthritis, autoantibodies target antigens with a variety of post-translational modifications like citrullination, carbamylation (a non-enzymatic, post-translational modification binding to isocyanic acid), and acetylation [10]. Citrullination might be a prerequisite for triggering the generation of ACPAs in susceptible RA patients [11][12][13]. Citrullinated autoantigens, abundant in RA synovial tissue, play a central role in the disease process. These are altered forms of proteins that arise due to post-translational modification involving the conversion of arginine to citrulline [14]. The citrullinated autoantigens can be recognized by antigen-presenting cells (APCs) like macrophages, neutrophils, and dendritic cells and present the antigen on their cell surface in conjunction with the HLA and travel to the draining lymph nodes where the APCs activate the T cells. Activation of self-reactive T cells triggers a cascade of immune events that contribute to the chronic inflammation and tissue damage observed in RA [15], which includes signaling molecules and cytokines like IFN-γ, IL-4, IL-10, and IL-13, stimulating B cells to differentiate into plasma cells to secrete autoantibodies.
ACPA targets are present in the synovium and synovial fluid [16], cartilage [17], lungs [18], and inflammatory cells like neutrophils and macrophages [19][20]. The development of autoantibody characteristics like the use of different isotypes, recognition of specific epitope(s), antibody avidity [21], and affinity, as well as the glycosylation status, reveal their relationship to RA risk factors and clinical phenotypes [10]. The HLA-DRB1 shared epitope, PTPN22, and smoking are associated with specific ACPA reactivities rather than anti-CCP levels [22]. A combination of smoking and HLA-SE alleles is significantly related to the development of some of the ACPA specificities closer to the onset of clinical symptoms, and these associations remained significant at diagnosis [23].
Interestingly, ACPAs can be detected years before the disease onset in a subgroup of patients, and at the onset of clinical symptoms, a broad isotype spectrum is observed [24][25]. Epitope spreading with increased recognition of citrullinated antigens occurs before the onset of RA [26]. An association of valine and leucine at HLA-DRB1 position 11 with radiographic progression in RA was reported to be independent of the shared epitope alleles but not ACPAs [27].
Similarly, RANKL (receptor activator of nuclear factor kappa-B ligand) concentrations are increased several years before the onset of arthritis symptoms, particularly in ACPA/RF/anti-CarP-positive individuals, all detectable earlier than RANKL. Positivity for RANKL and anti-CarP antibodies yielded the highest Larsen score in disease onset [28]. Combinations of IgM and IgA isotypes with ACPA specificities, including α-enolase (CEP-1), fibrinogen (Fib)β36-52, Fibα580-600, filaggrin (CCP-1), and anti-CCP2 antibodies, are associated with a shorter time to onset of clinical symptoms [29]. ACPAs are modified both in the constant and variable domains by the presence of N-linked glycans.
Recently, the presence of citrullinated autoantigens in platelets and the platelet-derived microparticles (PDPs) are identified as the potential targets of ACPAs in RA. Citrullinated forms of thrombospondin-1, β-actin, and platelet factor-4 (also known as CXCL4) are highly immunogenic and recognized by ACPAs [30]. ACPAs are associated with a more destructive disease phenotype, although their functional role might be pathogenic and protective depending on their specificity [31]. Previously, anti-citrullinated vimentin antibodies were shown to induce osteoclastogenesis and bone loss [32]. ACPAs can be of great help in identifying the disease activity in the early development of arthritis to treat the patients at an optimal period to prevent a more relapsing and chronic disease pattern, as observed in collagen-induced arthritis, a classical animal model of RA, with the development of epitope-specific, anti-collagen type II (CII) antibodies [33]. It has shown that autoantibodies specific to the CII triple-helical epitope bind and destabilize the cartilage independent of inflammation by an impairment of matrix synthesis on chondrocyte cultures with adverse effects on preformed cartilage and a significant proteoglycan depletion even in the absence of complement factor C5 [34]. Autoantibodies form immune complexes in the joints that attract immune effector cells [35], which initiate cytokine release and prolongs B cell survival pathways. Notably, the increased serum concentration of RF indicates a more aggressive articular disease and RF levels can help diagnose different subtypes of RA [4].
Glycosylation is a post-translational modification that affects most of the antibody’s mediated functions. FcγRs and complement binding to differentially glycosylated antibodies have altered functions like cellular cytotoxicity, phagocytosis, and cytokine secretion. Current studies illustrate that appropriate modification of Fc glycosylation of antibodies could attenuate the effector phase of arthritis and potentially be a future treatment option. In this context, it has been identified the importance of IgG Fc-glycosylation in arthritis. Streptococcal Endo-β- N-Acetylglucosaminidase (EndoS) secreted by Streptococcus pyogenes, which hydrolyses the β-1,4-di-N-acetylchitobiose core of the N-linked complex type glycan on the asparagine 297 of the γ-chains of IgG, induced suppression of local immune-complex-mediated arthritis. EndoS disturbed more extensive immune complex lattice formation on the surface of joints, as visualized using anti-C3c staining. Neither complement binding nor antigen–antibody binding per se was affected by the removal of IgG N-glycans by EndoS [36], and this enzyme treatment abolished the arthritogenicity of autoantibodies [37].
The IgG Fc part acts as a bridge between the innate and adaptive immune responses. It is regulated by N-glycosylation present in the variable structures, including agalactosylated and galactosylated forms, which are further modified by fucosylation and bisecting N-acetylglucosamine moieties. The bisecting proinflammatory N-acetylglucosamine moiety G0F was shown to be differentially regulated by estrogen via IgG glycosylation [38]. Similarly, phytoestrogens were found to protect the joints in experimental arthritis by increasing IgG glycosylation and reducing osteoclast activation [39]. The IL-23/TH17 axis could be a decisive factor in controlling the intrinsic inflammatory activities of autoantibodies, which trigger the clinical onset of arthritis [40].

References

  1. Smolen, J.S.; Breedveld, F.C.; Eberl, G.; Jones, I.; Leeming, M.; Wylie, G.L.; Kirkpatrick, J. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum. 1995, 38, 38–43.
  2. Buch, M.H.; Emery, P. New therapies in the management of rheumatoid arthritis. Curr. Opin. Rheumatol. 2011, 23, 245–251.
  3. Fang, Q.; Zhou, C.; Nandakumar, K.S. Molecular and Cellular Pathways Contributing to Joint Damage in Rheumatoid Arthritis. Mediat. Inflamm. 2020, 2020, 3830212.
  4. Fang, Q.; Ou, J.; Nandakumar, K.S. Autoantibodies as Diagnostic Markers and Mediator of Joint Inflammation in Arthritis. Mediat. Inflamm. 2019, 2019, 6363086.
  5. Volkov, M.; van Schie, K.A.; van der Woude, D. Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology. Immunol. Rev. 2020, 294, 148–163.
  6. Mastellos, D.C.; Hajishengallis, G.; Lambris, J.D. A guide to complement biology, pathology and therapeutic opportunity. Nat. Rev. Immunol. 2023, 1–24.
  7. Woodruff, T.M.; Nandakumar, K.S.; Tedesco, F. Inhibiting the C5-C5a receptor axis. Mol. Immunol. 2011, 48, 1631–1642.
  8. Nandakumar, K.S. Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues. Int. J. Mol. Sci. 2018, 19, 677.
  9. Rowley, M.J.; Nandakumar, K.S.; Holmdahl, R. The role of collagen antibodies in mediating arthritis. Mod. Rheumatol. 2008, 18, 429–441.
  10. Scherer, H.U.; van der Woude, D.; Toes, R.E.M. From risk to chronicity: Evolution of autoreactive B cell and antibody responses in rheumatoid arthritis. Nat. Rev. Rheumatol. 2022, 18, 371–383.
  11. Hill, J.A.; Bell, D.A.; Brintnell, W.; Yue, D.; Wehrli, B.; Jevnikar, A.M.; Lee, D.M.; Hueber, W.; Robinson, W.H.; Cairns, E. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J. Exp. Med. 2008, 205, 967–979.
  12. Schellekens, G.A.; de Jong, B.A.; van den Hoogen, F.H.; van de Putte, L.B.; van Venrooij, W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Investig. 1998, 101, 273–281.
  13. Trouw, L.A.; Rispens, T.; Toes, R.E.M. Beyond citrullination: Other post-translational protein modifications in rheumatoid arthritis. Nat. Rev. Rheumatol. 2017, 13, 331–339.
  14. Nguyen, H.; James, E.A. Immune recognition of citrullinated epitopes. Immunology 2016, 149, 131–138.
  15. Yap, H.Y.; Tee, S.Z.; Wong, M.M.; Chow, S.K.; Peh, S.C.; Teow, S.Y. Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development. Cells 2018, 7, 161.
  16. Van Beers, J.J.; Schwarte, C.M.; Stammen-Vogelzangs, J.; Oosterink, E.; Bozic, B.; Pruijn, G.J. The rheumatoid arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and beta-actin. Arthritis Rheum. 2013, 65, 69–80.
  17. Haag, S.; Schneider, N.; Mason, D.E.; Tuncel, J.; Andersson, I.E.; Peters, E.C.; Burkhardt, H.; Holmdahl, R. Identification of new citrulline-specific autoantibodies, which bind to human arthritic cartilage, by mass spectrometric analysis of citrullinated type II collagen. Arthritis Rheumatol. 2014, 66, 1440–1449.
  18. Ytterberg, A.J.; Joshua, V.; Reynisdottir, G.; Tarasova, N.K.; Rutishauser, D.; Ossipova, E.; Haj Hensvold, A.; Eklund, A.; Skold, C.M.; Grunewald, J.; et al. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: Identification and validation. Ann. Rheum. Dis. 2015, 74, 1772–1777.
  19. Spengler, J.; Lugonja, B.; Ytterberg, A.J.; Zubarev, R.A.; Creese, A.J.; Pearson, M.J.; Grant, M.M.; Milward, M.; Lundberg, K.; Buckley, C.D.; et al. Release of Active Peptidyl Arginine Deiminases by Neutrophils Can Explain Production of Extracellular Citrullinated Autoantigens in Rheumatoid Arthritis Synovial Fluid. Arthritis Rheumatol. 2015, 67, 3135–3145.
  20. Tutturen, A.E.; Fleckenstein, B.; de Souza, G.A. Assessing the citrullinome in rheumatoid arthritis synovial fluid with and without enrichment of citrullinated peptides. J. Proteome Res. 2014, 13, 2867–2873.
  21. Van Delft, M.A.M.; Verheul, M.K.; Burgers, L.E.; Rantapaa-Dahlqvist, S.; van der Helm-van Mil, A.H.M.; Huizinga, T.W.J.; Toes, R.E.M.; Trouw, L.A. The anti-carbamylated protein antibody response is of overall low avidity despite extensive isotype switching. Rheumatology 2018, 57, 1583–1591.
  22. Lundberg, K.; Bengtsson, C.; Kharlamova, N.; Reed, E.; Jiang, X.; Kallberg, H.; Pollak-Dorocic, I.; Israelsson, L.; Kessel, C.; Padyukov, L.; et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Ann. Rheum. Dis. 2013, 72, 652–658.
  23. Kokkonen, H.; Brink, M.; Hansson, M.; Lassen, E.; Mathsson-Alm, L.; Holmdahl, R.; Ronnelid, J.; Klareskog, L.; Rantapaa-Dahlqvist, S. Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis. Arthritis Res. Ther. 2015, 17, 125.
  24. Johansson, L.; Pratesi, F.; Brink, M.; Arlestig, L.; D’Amato, C.; Bartaloni, D.; Migliorini, P.; Rantapaa-Dahlqvist, S. Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis. Arthritis Res. Ther. 2016, 18, 127.
  25. Rantapaa-Dahlqvist, S.; de Jong, B.A.; Berglin, E.; Hallmans, G.; Wadell, G.; Stenlund, H.; Sundin, U.; van Venrooij, W.J. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 48, 2741–2749.
  26. Van der Woude, D.; Rantapaa-Dahlqvist, S.; Ioan-Facsinay, A.; Onnekink, C.; Schwarte, C.M.; Verpoort, K.N.; Drijfhout, J.W.; Huizinga, T.W.; Toes, R.E.; Pruijn, G.J. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann. Rheum. Dis. 2010, 69, 1554–1561.
  27. Van Steenbergen, H.W.; Raychaudhuri, S.; Rodriguez-Rodriguez, L.; Rantapaa-Dahlqvist, S.; Berglin, E.; Toes, R.E.; Huizinga, T.W.; Fernandez-Gutierrez, B.; Gregersen, P.K.; van der Helm-van Mil, A.H. Association of valine and leucine at HLA-DRB1 position 11 with radiographic progression in rheumatoid arthritis, independent of the shared epitope alleles but not independent of anti-citrullinated protein antibodies. Arthritis Rheumatol. 2015, 67, 877–886.
  28. Johansson, L.; Arlestig, L.; Kokkonen, H.; Brink, M.; Rantapaa-Dahlqvist, S. An increased concentration of receptor activator of nuclear factor kappa-B ligand pre-dates the onset of rheumatoid arthritis. Rheumatology 2017, 56, 2190–2196.
  29. Brink, M.; Hansson, M.; Mathsson-Alm, L.; Wijayatunga, P.; Verheul, M.K.; Trouw, L.A.; Holmdahl, R.; Ronnelid, J.; Klareskog, L.; Rantapaa-Dahlqvist, S. Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis. Arthritis Res. Ther. 2016, 18, 43.
  30. Xu, M.; Du, R.; Xing, W.; Chen, X.; Wan, J.; Wang, S.; Xiong, L.; Nandakumar, K.S.; Holmdahl, R.; Geng, H. Platelets derived citrullinated proteins and microparticles are potential autoantibodies ACPA targets in RA patients. Front. Immunol. 2023, 14, 1084283.
  31. Ge, C.; Holmdahl, R. The structure, specificity and function of anti-citrullinated protein antibodies. Nat. Rev. Rheumatol. 2019, 15, 503–508.
  32. Harre, U.; Georgess, D.; Bang, H.; Bozec, A.; Axmann, R.; Ossipova, E.; Jakobsson, P.J.; Baum, W.; Nimmerjahn, F.; Szarka, E.; et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J. Clin. Investig. 2012, 122, 1791–1802.
  33. Bajtner, E.; Nandakumar, K.S.; Engstrom, A.; Holmdahl, R. Chronic development of collagen-induced arthritis is associated with arthritogenic antibodies against specific epitopes on type II collagen. Arthritis Res. Ther. 2005, 7, R1148–R1157.
  34. Nandakumar, K.S.; Bajtner, E.; Hill, L.; Bohm, B.; Rowley, M.J.; Burkhardt, H.; Holmdahl, R. Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. Arthritis Rheum. 2008, 58, 184–196.
  35. Van Delft, M.A.M.; Huizinga, T.W.J. An overview of autoantibodies in rheumatoid arthritis. J. Autoimmun. 2020, 110, 102392.
  36. Nandakumar, K.S.; Collin, M.; Happonen, K.E.; Lundstrom, S.L.; Croxford, A.M.; Xu, B.; Zubarev, R.A.; Rowley, M.J.; Blom, A.M.; Kjellman, C.; et al. Streptococcal Endo-beta-N-Acetylglucosaminidase Suppresses Antibody-Mediated Inflammation In Vivo. Front. Immunol. 2018, 9, 1623.
  37. Nandakumar, K.S.; Collin, M.; Olsen, A.; Nimmerjahn, F.; Blom, A.M.; Ravetch, J.V.; Holmdahl, R. Endoglycosidase treatment abrogates IgG arthritogenicity: Importance of IgG glycosylation in arthritis. Eur. J. Immunol. 2007, 37, 2973–2982.
  38. Ercan, A. Sex effect on the correlation of immunoglobulin G glycosylation with rheumatoid arthritis disease activity. Turk. J. Biol. 2020, 44, 406–416.
  39. Du, N.; Song, L.; Li, Y.; Wang, T.; Fang, Q.; Ou, J.; Nandakumar, K.S. Phytoestrogens protect joints in collagen induced arthritis by increasing IgG glycosylation and reducing osteoclast activation. Int. Immunopharmacol. 2020, 83, 106387.
  40. Pfeifle, R.; Rothe, T.; Ipseiz, N.; Scherer, H.U.; Culemann, S.; Harre, U.; Ackermann, J.A.; Seefried, M.; Kleyer, A.; Uderhardt, S.; et al. Regulation of autoantibody activity by the IL-23-T(H)17 axis determines the onset of autoimmune disease. Nat. Immunol. 2017, 18, 104–113.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Immunology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Kutty Selva Nandakumar
,
Qinghua Fang
,
Isabella Wingbro Ågren
,
Zoe Fuwen Bejmo
View Times: 269
Revisions: 2 times (View History)
Update Date: 07 Nov 2023
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback